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Abstract
The role of angiotensin II (Ang II) in skeletal muscle is poorly understood. We report that pharmacological inhibition of
Ang II signaling or ablation of the AT1a receptor significantly impaired skeletal muscle growth following myotrauma, in
vivo, likely due to impaired satellite cell activation and chemotaxis. In vitro experiments demonstrated that Ang II
treatment activated quiescent myoblasts as evidenced by the upregulation of myogenic regulatory factors, increased
number of b-gal+, Myf5-LacZ myoblasts and the acquisition of cellular motility. Furthermore, exogenous treatment
with Ang II significantly increased the chemotactic capacity of C2C12 and primary cells while AT1a
2/2 myoblasts
demonstrated a severe impairment in basal migration and were not responsive to Ang II treatment. Additionally, Ang II
interacted with myoblasts in a paracrine-mediated fashion as 4 h of cyclic mechanical stimulation resulted in Ang
II-induced migration of cocultured myoblasts. Ang II-induced chemotaxis appeared to be regulated by multiple
mechanisms including reorganization of the actin cytoskeleton and augmentation of MMP2 activity. Collectively, these
results highlight a novel role for Ang II and ACE inhibitors in the regulation of skeletal muscle growth and satellite cell
function.
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Introduction
Skeletal muscle is composed of post-mitotic, multinucleated
fibres. The growth, regeneration and routine maintenance
(through turnover of myonuclei) is largely dependent on a
population of muscle stem cells, referred to as ‘‘satellite cells’’.
These cells are maintained in a state of quiescence under basal
conditions and become activated in response to intrinsic and
environmental cues associated with muscle damage, and contrac-
tion. [1]. The activation of muscle satellite cells are characterized
by the increased expression of the myogenic regulatory factors
such as MyoD and Myf5 [2] and immediate early genes such as
cfos [3]. Once activated, satellite cells migrate to the site of injury,
proliferate and subsequently differentiate and fuse to restore
skeletal muscle architecture in a process referred to as the
myogenic program [4,5]. Although much is understood about the
transcriptional networks governing the myogenic program [6–11],
little is known regarding the upstream signals or soluble factors
influencing myogenic regulatory factor expression and satellite cell
function.
Specifically, there is a paucity of information regarding the
factors that induce the activation of satellite cells with hepatocyte
growth factor being the only reliably identified cytokine [12,13].
Similarly, the temporal kinetics, soluble factors, or signaling
cascades regulating satellite cell migration are poorly understood.
Indeed, chemotaxis is integral to repair and growth of skeletal
muscle as satellite cells are required to migrate great distances to
sites of myotrauma [14], and properly align to undergo
differentiation and fusion. Interestingly, hepatocyte growth factor
signaling has also been implicated in myoblast chemotaxis [15]
suggesting a link between satellite cell activation and cellular
motility.
Angiotensin II (Ang II) has been extensively studied in the
context of its vaso-regulatory properties and the pharmacological
inhibition of Ang II signaling to reduce blood pressure represents
the most widely-prescribed anti-hypertensive therapy [16].
However, localized tissue renin-angiotensin systems (RAS) have
been identified suggesting that Ang II may have wide ranging
effects in addition to its systemic role in vasoregulation. For
example, Ang II is now known to influence such diverse processes
as cell proliferation, hypertrophy [17,18] and migration [19–21].
Cultured skeletal muscle myoblasts and myotubes possess a local
Ang II signaling system [22]; however, its function remains poorly
understood. Importantly, it was reported that inhibition of Ang II
signaling resulted in near complete attenuation of skeletal muscle
hypertrophy in a model of synergist ablation [23,24], suggesting
that Ang II may regulate skeletal muscle hypertrophy. Regrettably,
the precise role of a local RAS in skeletal muscle regeneration,
growth and maintenance remains largely unknown.
The purpose of this investigation was to assess the role of Ang II
in regulating the growth and repair of skeletal muscle, in vivo,a s
well as myoblast function in vitro. In this manuscript we report that
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ablation of the Ang II type Ia receptor (AT1a) resulted in a
significant impairment in skeletal muscle growth following
cardiotoxin (CTX)-induced injury. Furthermore, in vitro experi-
ments indicated that Ang II regulates the early satellite cell
response as exogenous treatment of quiescent myoblasts with Ang
II resulted in an upregulation of myogenic regulatory factor
expression indicating enhanced activation, as well as an increased
chemotactic capacity attributable to signaling through AT1. Ang
II-induced migration occurred through reorganization of the
intracellular actin cytoskeleton and enhanced matrix metallopro-
teinase-2 (MMP2) activity. We also report that Ang II can function
in a paracrine fashion signaling neighboring myoblasts to migrate
in a coculture environment. Collectively, these results identify a
novel role for Ang II in the regulation of skeletal muscle growth
and muscle stem cell function. Furthermore, these results suggest
that the widely prescribed anti-hypertensive drug, captopril, may
have adverse affects on skeletal muscle growth and repair.
Methods
Animals/experimental procedures
Ten-week-old C57Bl/6 mice (study-1, n=10 per group) and
fourteen-week-old AT1a
2/2 mice and aged matched C57Bl/6
controls (study-2, n=4 per group) (Jackson laboratories, USA)
were utilized. Study-1 C57Bl/6 mice were supplemented with
either normal drinking water or captopril (0.5 mg/mL, Sigma,
Canada) treated drinking water three days prior to and throughout
the experimental protocol. Animals were subjected to either
bilateral (study-1) or unilateral (study-2) injections of CTX (25 ml
at 10 mM, spread over three injections sites: proximal, mid, and
distal sites of the TA) into the TA muscle and tissues were
harvested 3, 10 and 21 days post injection (study-1) or 4, 7, 14 and
21 days post injection (study-2). Also, for reference of normal
skeletal muscle architecture, a non-injured, non-supplemented
group (n=8) was included (study-1). Ethics approval was granted
by the McMaster University Animal Research Ethics Board (AUP
06-09-51) and conformed to the guidelines of the Canadian
Council on Animal Care.
Histology
Muscles were formalin-fixed, paraffin-embedded and stained
with hematoxylin and eosin (H&E) to reveal skeletal muscle
architecture and viewed on a Nikon Eclipse 90i. Mean muscle
fibre CSA was calculated in a blinded fashion by analyzing 300
regenerating fibres on randomly selected fields of view per animal
using Nikon NIS Elements 3.0 software. b-gal activity in Myf5-
LacZ cells was visualized as previously described [25]. Briefly, cells
were fixed in 2 mM MgCl2 and 0.25% glutaraldehyde in PBS for
10 min followed by washing and overnight incubation in 5 mM
potassium ferrocyanide, 5 mM potassium ferricyanide, 2 mM
MgCl2, 4 mg/ml X-gal and 0.02% NP40 in PBS at 37uC. Cells
were then washed in PBS, fixed for 10 min with 4% PFA and
mounted.
Cell culture
All cultures were maintained at 37uCi n5 %C O 2. Primary
myoblasts were isolated from wild-type C57Bl/6 and AT1a
2/2
mice as previously described [26] and cultured in primary growth
media (PGM, 20% FBS in Hams F10 with 2.5 ng/mL bFGF and
antibiotics). Myf5-LacZ myoblasts were a generous gift from Dr.
Michael Rudnicki (Ottawa Hospital Research Institute, Ottawa
Canada) and were cultured in PGM. C2C12 myoblasts were
cultured in growth medium (GM, DMEM supplemented with
10% fetal bovine serum and antibiotics) or serum free medium
(SFM, DMEM supplemented with antibiotics). When indicated,
C2C12 and Myf5-LacZ myoblasts were rendered quiescent
through 72 h of culturing in a methocellulose supplemented
medium that prevented cell adhesion as described previously [27].
Flow cytometery
The effect of Ang II treatment (24 h, 10 mM) on cell cycle
kinetics of methocellulose cultured C2C12 cells was determined
using PI staining or a commercially available BrdU/7AAD kit as
per the manufactures instructions (cat#559619, BD pharmagen,
USA) and analyzed using flow cytometry (Epics Altra, Beckman
Coulter, USA).
RNA isolation, reverse transcription and quantitative real-
time polymerase chain reaction
RNA was isolated from quiescent C2C12 myoblasts (with and
without Ang II (10 mM) treatment for 3 h, 6 h or 12 h) using the
RNeasy method according to the manufactures instructions
(Qiagen Sciences, USA) and analyzed using quantitative RT-
PCR (qRT-PCR). Gene expression fold change was calculated
using the delta-delta Ct method [28] using ribosomal protein L32
as a housekeeping gene. Primer sequences can be found in Table 1.
Transwell/invasion/checkerboard assays
Transwell assays were conducted using proliferating or
quiescent C2C12 myoblasts and primary or AT1a
2/2 myoblasts
as described previously [29] with minor modifications using 6 or
24 well, 8 mm pore transwell systems. Cells were allowed to
migrate for 12 h with the lower chamber of the well containing
GM, 20% FBS in DMEM, PGM or SFM with or without Ang II
(10 mM) or an MMP2 inhibitor (1 mM; cat# 44424, Calbiochem,
USA) where indicated. Invasion and checkerboard assays were
performed in the same fashion as migration assays with the
exception that transwells were pre-coated with 1% gelatin or
media on either the top or the bottom of the transwell was
supplemented with Ang II (10 mM). Migration was assessed by
staining the cells with crystal violet, removing the cells on the
upper side of the transwell and counting the number of migrated
cells in 15 random fields of view at 40x magnification using Zeiss
Axiovert 200 microscope (Carl Zeiss Canada Ltd.) or by
solubilizing the cells in 1% triton X-100 and measuring the
absorbance of the triton X-100 solution using an Ultraspec 3000
Pro (GE Healthcare, USA) at 595 nm.
Under agarose (UA) migration assay
To further assess the chemotactic capacity of C2C12 cells in
response to Ang II treatment, an under agarose migration assay
Table 1. Primer sequences used.
Gene Forward primer Reverse primer
AT1 ACAGTGATATTGGTGTTCTCAATGAAA CCATTGTCCACCCGATGAA
cfos GAATGGTGAAGACCGTGTCA TGCAACGCAGACTTCTCATC
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polymerized in 10% FBS in DMEM in 35 mm culture plates and
3 wells were cut. C2C12 cells were added to the centre well while
GM with or without Ang II (100 mM) was added to the outer wells
and allowed to incubate for 14 h. The total number of cells and
distance migrated under the agarose was analyzed using a Zeiss
Axiovert 200 microscope (Carl Zeiss Canada Ltd). Maximal
migration distance was calculated by averaging the distance of the
top 15 migrating cells per sample.
Immunohistochemistry
C2C12 cells were plated into the centre well of an under
agarose migration plate while GM with or without Ang II
(100 mM) was then added to one of the outer wells and incubated
for 6 h. Cells were fixed in 4% PFA for 10 min (or 5 min, followed
by dehydration in ethanol for co-staining). IHC staining for AT1
receptor was done using anti-AT1 (cat# SC-1173, Santa Cruz,
USA) and revealed with anti-rabbit Alexa 488 secondary antibody
(Molecular Probes, USA). Filamentous actin was visualized with
TRITC-conjugated phalloidin (0.2 mg/mL, cat#P1951, Sigma-
Aldrich, Canada) and incubated simultaneously overnight at 4uC
with anti-AT1 for costaining and counterstained with DAPI.
Mechanical stretch/coculture migration assay
Flexible bottom culture plates (Flexcell International, USA)
were modified to accommodate a transwell insert. C2C12
myoblasts were pretreated for 36 h in either GM or GM
supplemented with captopril (10 mM) to inhibit endogenous
Ang II production. 2610
5 cells were seeded onto type I collagen
coated flex-cell plates while 5610
4 cells were seeded into the upper
well of a transwell insert and placed into the flex-cell plates. Cells
were subjected to a 4 h cyclic strain protocol (of 0.1 Hz at 20%
strain) applied using the FX-4000 Tension Plus (Flexcell
International, USA) in the presence or absence of captopril. After
20 h, cell migration was assessed as described above.
Gelatin Zymography
C2C12 myoblasts were cultured in GM and treated with Ang II
(10 mM) for 48 h and media and total protein was collected
analyzed using gelatin zymography as previously described [31].
20 ml of media or 7.5 mg of protein was loaded into a 10%
polyacrylamide gel containing 1% gelatin and resolved for 90 min
at 100 V. Gels were incubated in 2.5% triton X-100 for 1 h,
washed in H2O for 2620 min, and incubated for 20 h at 37uCi n
a 50 mM Tris-HCl buffer, pH 8.0, containing 5 mM calcium
chloride. Gels were then fixed with 50% methanol, 10% acetic
acid containing 0.25% Coomassie Blue. Bands appear clear
against the stained gel and were visualized using an Alpha
Innotech FluroChem SP and quantified using Alphaease software.
Statistical analysis
Analysis of in vivo measures was done by two-way ANOVA. In
vitro experiments were analyzed using t-tests and one-way
ANOVA where appropriate. T-tests were also performed on gene
expression fold change for qRT-PCR analysis.
Results
Ang II signaling mediates skeletal muscle growth
following CTX injury
To determine the in vivo consequence of impaired Ang II
signaling on muscle regeneration and growth we injected AT1a
2/2
or ACE inhibitor (captopril) treated mice with CTX to induce
myotrauma. Analysis of H&E stained TA cross-sections revealed
that in comparison to controls, captopril supplemented mice
presented with a decrease in muscle fibre cross-sectional area
(CSA) of ,25% 21 days following injury (Figure 1A, B, C;
p,0.05) while no differences were observed between groups 10
days post injection. 21 days also appeared to be sufficient time for
control animals to fully regenerate as fibre CSA was not different
from uninjured (UI) mice while captopril treated mice still
demonstrated a significant ,25% reduction in CSA relative to
UI mice (Figure 1C). Importantly, CTX-induced damage was
evident in over 90% of muscle fibres in both groups as
represented by the presence of central nuclei in almost all fibres
21d post injury, and the fibre CSA differences between groups
was overt and evident in 10X images (Figure S6). Analysis
of small (,1500 mm), medium (1500 to 3000 mm) and large
(.3000 mm) size fibres revealed an increased frequency of small
fibres and a decrease in large fibres with captopril treatment
(Figure 1D). Furthermore, when muscle fibre CSA was analyzed
from days 10–21 post injury we observed that captopril treatment
significantly impaired muscle growth as control animals demon-
strated an 81% increase in CSA while captopril treated mice
increased by only 27% (Figure 1C). To investigate the role of Ang
II receptor sub-type we repeated similar experiments inducing
regeneration in AT1a
2/2 mice. In agreement with the captopril
treated animals, AT1a
2/2 mice also revealed impaired skeletal
muscle growth following the formation of myofibres with
significant decreases in fibre CSA of ,35% and ,25% at 14d
and 21d respectively compared to controls (Figure 1E). When the
rate of growth was determined between day 7–14 post injury, a
110% increase in fiber CSA was documented in the WT mice
while a non-significant 19% increase was observed in AT1a
2/2
mice (Figure 1E). Importantly, normal skeletal muscle growth was
not impaired in AT1a
2/2 mice as no differences were observed in
myofibre CSA between uninjured WT and AT1a
2/2 mice
(Figure S7), however our data suggests that post-natal induced
muscle growth following injury requires Ang II.
Ang II activates quiescent myoblasts without enhancing
proliferation
To investigate the mechanisms responsible for repressed muscle
growth, due to inhibition of Ang II signaling, we analyzed the
effect of Ang II treatment on myoblast function. The use of
methocellulose culture suspension to induce quiescence has
previously been validated and is a valuable tool to assess myoblast
activation [32–34]. To confirm quiescence of methocellulose
treated cells we analyzed the cell cycle kinetics using propidium
iodide staining and flow cytometry following 72 h of methocellu-
lose treatment. When compared to actively dividing C2C12
myoblasts, 72 h of methocellulose suspension induced synchroni-
zation of cells in G1, reduced the number of actively dividing cells
(S-phase cells) to less than 1.5% (Figure S1) and decreased the
number of cells progressing through the cell cycle (28% in controls
vs. 11% in methocellulose treated, (Figure S1)). To assess if Ang II
could activate myoblasts, quiescent C2C12 cells were treated with
Ang II for 3, 6 or 12 h. Treatment of quiescent cells with Ang II
induced the upregulation of mRNA species characteristic of
activated myoblasts such as increases in the myogenic regulatory
factor Myf5 (2.5-fold) and MyoD (6-fold) at 3 h and 6 h
respectively as well as Pax7 (7-fold, 6 h) (Figure 2A, B, C). Ang
II treatment also led to a significant increase in the cell cycle gene
cyclin D1 as well as an early (3 h) increase in cfos gene expression
(Figure 2D, E), which has been proposed to be one of the earliest
events associated with satellite cell activation in vivo [3].
Additionally, Ang II treatment increased the expression of the
Angiotensin II and Muscle Regeneration
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observed following 6 h of treatment (Figure 2F). Since satellite cell
activation is characterized by an upregulation of Myf5 [5] and to
confirm that Ang II activated quiescent primary myoblasts, the
effect of 6 h of Ang II treatment was assessed in Myf5-LacZ
primary myoblasts following 72 h of methocellulose culture
suspension. In comparison to actively dividing cells, methocello-
lose culture reduced the number of b-galactosidase (b-gal)+ cells
from ,77% to ,21% (Figure 3A; p,0.05) confirming the
quiescence of these cells. However, Ang II treatment of quiescent
myoblasts successfully increased the number of b-gal+ cells by
,75% (Figure 3A; p,0.05).
Next, we wanted to assess whether the activation of quiescent
myoblasts induced cell motility. Therefore, we analyzed the
migratory capacity of quiescent myoblasts treated with serum free
media (methocel), Ang II or 20% FBS supplemented media
(control), which is a known inducer of myoblast activation. When
compared to controls, cells treated with SFM displayed a severe
impairment of migratory capacity (,70% reduction, Figure 3B)
confirming that quiescent cells must become activated in order to
undergo migration. Interestingly, when comparing the migratory
activity of cells treated with SFM or Ang II, we demonstrate that
both direct treatment and a concentration gradient of Ang II
significantly increased the chemokinetic migration of cells by
,75% (Figure 3B) demonstrating a functional measure of
myoblast activation.
Since we demonstrated that Ang II activates quiescent cells and
upregulates key transcription factors necessary for myoblast
proliferation (i.e. Myf5, cyclin D1), we tested whether Ang II
possessed the ability to induce quiescent cells to proliferate.
Interestingly, no differences were observed between groups in
either the number of BrdU positive cells or the cell cycle kinetics in
response to 24 h of Ang II treatment of quiescent myoblasts
(Figure S2). Additionally, 6 h of BrdU incorporation into primary
myoblasts treated with Ang II was not different from cells treated
with control media providing further evidence that Ang II alone
does not play a role in cell proliferation (Figure S8). Collectively,
these results demonstrate that Ang II activates myoblasts and
initiates cell cycle entry but does not directly induce proliferation
of quiescent myoblasts.
Ang II signals through the AT1a receptor to induce
chemotaxis of proliferating cells
Since the process of myoblast chemotaxis is poorly understood
and Ang II has been implicated in the motility of several cell types
[19–21], we assessed the role of Ang II in regulating myoblast
chemotaxis using an assay commonly utilized to assess inflamma-
tory cell migration [30]. Under agarose migration analysis (Figure
S3) revealed a robust 133% increase in the number of C2C12 cells
that migrated out of the centre well in response to an Ang II
concentration gradient (Figure 4C) as well as increasing the
maximal distance migrated by ,50% (Ang II-298.3 mm vs. Con-
201.7 mmp ,0.05; Figure 4D). This increase in C2C12 migration
was also evident using transwell assays where Ang II treatment
induced a 30% increase in migratory capacity (Figure 4B). There
are two distinct forms of myoblast motility: 1. chemokinesis,
analogous to stochastic movements, and 2. chemotaxis, analogous
to directed homing. Checkerboard assays revealed that when
activated myoblasts were treated directly with Ang II no increase
in migration was observed; however, when exposed to a
Figure 1. Inhibition of Ang II signaling abrogates skeletal muscle growth following CTX injury. Representative H&E stains of TA cross-
sections of (A) control and (B) captopril treated mice 21 days after CTX injection (both photos - 40x magnification). C) Mean muscle fibre CSA of
control and captopril treated mice 10 and 21 days following CTX injection. Note: e - indicates CSA of uninjured mice (n=6 per group). D) Distribution
of small (,1500 mm
2), medium (1500–3000 mm
2) and large (.3000 mm
2) size muscle fibres of control and captopril treated mice 21 days following
CTX injection. E) Analysis of muscle fibre CSA of control and AT1a
2/2 mice 7, 14 and 21 days following CTX injection (n=4 per group). Data are
presented as mean 6 s.e.m, *indicates a significant difference (p,0.05) from control.
doi:10.1371/journal.pone.0015212.g001
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number of migrating cells was demonstrated (Figure S4A). To
confirm that Ang II augments primary myoblast migration and to
delineate which receptor subtype was activated during Ang II-
induced myoblast chemotaxis, primary myoblasts were harvested
from C57Bl/6 (wild-type; WT) and AT1a
2/2 mice. Transwell
assays revealed that exogenous Ang II treatment significantly
increased primary myoblast chemotaxis by 43% while AT1a
2/2
myoblasts demonstrated a profound (,62%) inhibition (p,0.05)
of migratory capacity and did not respond to Ang II treatment
(Figure 4A).
We have previously demonstrated that myoblasts locally
produce Ang II and express a ‘‘stretch-responsive’’ local
angiotensin signaling system [22]. Based on these findings, we
explored the possibility that the mechanical stretch of myoblasts
could induce the production of Ang II, which in turn, could
initiate the migration of cocultured myoblasts. Our results
demonstrate a significant 17% increase in myoblast migration in
Figure 3. Ang II treatment results in the activation of primary myoblasts and the acquisition of motility. A) Actively dividing Myf5-LacZ
myoblasts (control) were cultured in PGM while quiescent Myf5-LacZ myoblasts were treated with Hams F10 (methocel) or Ang II for 6 h and the
percentage of b-gal+ cells was assessed (n=6 per group). B) Quiescent C2C12 myoblasts were treated with SFM (methocel), Ang II directly (Ang II
treatment), an Ang II concentration gradient (Ang II on bottom) or 20% FBS (control) and migration was measured using transwells (n=6 per group).
Data are presented as mean 6 s.e.m, *indicates a significant difference (p,0.05) from control.
doi:10.1371/journal.pone.0015212.g003
Figure 2. Ang II treatment upregulates mRNAs found within activated satellite cells. qRT-PCR analysis of (A) Myf5, (B) MyoD, (C) Pax7, (D)
cfos, (E) cyclin D1, and (F) AT1 in quiescent C2C12 myoblasts in response to Ang II treatment for 3, 6 or 12 h (n=6 per group). Data are presented as
mean 6 s.e.m, *indicates a significant difference (p,0.05) from control.
doi:10.1371/journal.pone.0015212.g002
Angiotensin II and Muscle Regeneration
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(Figure 5A) that was abolished when myoblasts underwent
mechanical stretch in the presence of captopril (Figure 5B).
Moreover, captopril treatment of unflexed cells also significantly
inhibited the basal migration of myoblasts (p,0.05). Collectively,
these data indicate that Ang II signaling through the AT1a
receptor is a mediator of myoblast chemotaxis and that Ang II can
signal chemotaxis in a paracrine fashion.
Ang II-induced chemotaxis is mediated by multiple
mechanisms including cytoskeletal reorganization and
increased MMP2
Since proper actin filament assembly has been hypothesized to
be a prerequisite for directed cellular motility [35], and implicated
in Ang II-induced migration of other cell types [36,37], we treated
C2C12 myoblasts with a concentration gradient of Ang II and
assessed the number of cells displaying altered cytoskeletal
characteristics. TRITC-conjugated phalloidin staining of the actin
cytoskeleton revealed that Ang II treatment increased the number
of cells displaying lamellipodial projections by 111% (Figure 6D–
F). Interestingly, IHC costaining of AT1 and phalloidin revealed
that AT1 translocates to the leading edge of the cell and was
concentrated in lamellipodia (Figure S5). These results indicate
that Ang II signaling induced cellular polarization and reorgani-
zation of the actin cytoskeleton. Another important component of
cell migration is the ability of a cell to degrade its extracellular
environment to promote cell motility. Therefore, we assessed
whether Ang II influenced enzyme activity involved in the
breakdown of the extracellular matrix (ECM). Gelatin zymogra-
phy analysis demonstrated an ,40% increase in total MMP2
Figure 4. Ang II signals through the AT1a receptor to increase myoblast chemotaxis. Analysis of (A) primary WT, AT1a
2/2 and (B) C2C12
myoblast migration through transwells in response to Ang II treatment (n=10 per group). Analysis of (C) total number and (D) maximal distance of
C2C12 myoblasts following 12 h of UA migration (n=16 per group). Representative images of Ang II treated (E) and control (F) C2C12 cells following
12 h of UA migration. *indicates a significant difference (p,0.05) from control.
doi:10.1371/journal.pone.0015212.g004
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of C2C12 cells treated with Ang II. These results are in agreement
with in vitro invasion assays, which demonstrated that Ang II
treatment of myoblasts induced a significant increase in the
number of cells invading the gelatin coated transwells (Figure
S4B), presumably by inducing the enzymes involved in the
degradation of extracellular matrix proteins. To confirm the
importance of Ang II-induced MMP2 activity in myoblast
migration, a transwell assay was conducted in the presence of an
MMP2 inhibitor (MMP2I). Results revealed that inhibition of
MMP2 did not appear to affect basal migration of C2C12 cells,
however, when cells were treated with Ang II and the MMP2I, the
observed increase in migratory capacity was completely abolished
(Figure 6C). These data suggest that Ang II-stimulated chemotaxis
was regulated, at least in part, by MMP2 activity.
Discussion
The regeneration and growth of skeletal muscle is largely
dependent on the capacity of muscle satellite cells to efficiently
respond to directed cues that signal the activation, motility and
progression of satellite cells through the myogenic program. An
impairment of any of these processes could result in the decreased
capacity for repair or growth. Consequently, we have identified
Ang II as a novel regulator of muscle stem cell chemotaxis, an
activator of quiescent myoblasts and a necessary factor for induced
myofibre growth following injury.
In recent years, Ang II has been described as having wide
ranging biological effects independent of its vasoactivity [38]. The
function of Ang II signaling in skeletal muscle and associated
muscle satellite cells remains incompletely described with the
potential to influence muscle hypertrophy [23,24]. Our in vivo
observations support a regulatory role for Ang II in mediating
muscle fibre growth likely through muscle satellite cell activation
and chemotaxis. Specifically, we demonstrate that both captopril
treatment and ablation of the AT1a receptor resulted in a similar
inhibition of fibre growth highlighting a role for AT1 mediated
signaling. Importantly, muscle fibre CSA was not different
between uninjured control and AT1a
2/2 mice. This indicates
that Ang II likely does not influence embryonic or neonatal muscle
development but appears to only influence postnatal myogenesis
during regeneration and growth.
To explain the observed inhibition of skeletal muscle growth
due to captopril treatment, we focused our analysis on the
Figure 5. Mechanical stretch stimulates Ang II-mediated
chemotaxis in coculture. Analysis of C2C12 chemotaxis in response
to coculture with myoblasts exposed to 4 h of cyclic mechanical stretch
in the absence or presence of captopril (n=6 per group). *indicates a
significant difference (p,0.05) from control-unflexed. All data are
presented as mean 6 s.e.m.
doi:10.1371/journal.pone.0015212.g005
Figure 6. Ang II treatment regulates myoblast chemotaxis through increased MMP2 and actin cytoskeletal reorganization. A) Gelatin
zymography analysis of total MMP2 activity within cell culture media and (B) cell lysates of C2C12 myoblasts treated with Ang II (n=6 per group). C)
AnalysisofthemigrationofC2C12myoblaststreatedwithVehicle,Vehicle+AngII,MMP2 inhibitororAngII+MMP2inhibitor(n=6 pergroup).F)Analysis
ofTRITC-conjugatedphalloidin stainingof(D)controland(E) AngIItreatedC2C12myoblasts(20x magnification,n=12pergroup).Note:arrowsindicate
cells displaying lamellipodial projections. Data are presented as mean 6 s.e.m, *indicates a significant difference (p,0.05) from control.
doi:10.1371/journal.pone.0015212.g006
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cells to muscle repair since very little is known regarding the
factors that mediate this phase. We demonstrate that Ang II
induced the expression of mRNAs and protein known to be
upregulated in activated myoblasts such as the myogenic
regulatory factors Myf5, MyoD and Pax7. Interestingly, the
temporal expression of these genes in response to Ang II treatment
is in agreement with in vivo data demonstrating that satellite cell
activation is represented by an early upregulation of Myf5
followed by increased MyoD expression [39]. Importantly, Ang
II treatment lead to the production of functional Myf5 protein in
cultured primary cells proving that effects of Ang II on myoblast
activation are not restricted to C2C12 cells. We also demonstrated
that the activation of myoblasts resulted in acquired cellular
motility, which likely serves to upregulate the migratory machinery
necessary to respond to chemotactic signals. It is interesting to note
that Ang II treatment of quiescent cells induced the same
magnitude increase in chemokinesis of C2C12 cells as that
observed in the number of b-gal+ Myf5-LacZ cells, further
supporting the relationship between Ang II induced activation and
cellular motility. These results suggest that early responses of
satellite cells to myotrauma may be coordinated by Ang II as it
plays a pleiotropic role in activating cells as well directing their
subsequent chemotactic response.
Our data also demonstrate that although Ang II activated
myoblasts, it did not alter cell cycle kinetics of quiescent cells.
These data suggest that Ang II primarily functions to activate
myoblasts but may act in concert with other factors to induce full
cell cycle entry and proliferation. This theory is supported by
Hlaing and colleagues [40] who demonstrated that Ang II
treatment of serum starved C2C12 cells had no effect on
myoblast proliferation but induced the transient activation
of Cdk4, Rb phosphorylation and the subsequent release of
HDAC1. However, they also reported that although Ang II
transcriptionally activated E2F-1, this complex did not dissociate
from the Rb protein subsequently suppressing genes necessary for
cell cycle progression.
The chemotaxis of muscle stem cells to the site of injury is an ill
defined, necessary component of the early response of satellite cells
to myotrauma. Using several techniques, the present experiments
demonstrate that exogenous Ang II treatment significantly
increased both primary and C2C12 chemotaxis. We have
previously reported that myoblasts have the ability to secrete
Ang II and that mechanical stimulation of C2C12 myoblasts
resulted in the upregulation of RAS family member gene
expression [22]. Here, we demonstrate that mechanical stretch
of cells induced the chemotaxis of cocultured myoblasts through
Ang II mediated mechanism(s). Although the magnitude of
increase in migration was less than that induced by Ang II
treatment, the concentration of Ang II released into the culture
media was likely magnitudes lower, highlighting the robustness of
the effect of Ang II on motility. These results suggest that
mechanical stimulation due to muscle contraction in vivo may
stimulate Ang II release that functions to recruit muscle satellite
cells to the site of injury. Ang II treatment of both quiescent and
proliferating cells resulted in enhanced cellular motility with
quiescent cells responding to Ang II treatment chemokinetically
and proliferating cells undergoing chemotaxis. Based on our
results, we propose that Ang II functions to activate quiescent
myoblasts subsequently increasing their motility but then serves to
direct the homing response following their activation.
The source of Ang II during muscle regeneration or the
molecular mechanisms regulating its production remain unknown.
We have previously demonstrated that muscle cells express a local
Ang II signaling system with the ability to secrete Ang II into the
culture media. Therefore, regenerating muscle fibres could
potentially signal the activation and chemotaxis of satellite cells
to the site of injury through increased Ang II release. Furthermore,
based on our coculture experiments, the myoblasts themselves may
increase Ang II secretion to direct the regenerative response
following myotrauma. It is important to note that angiotensin II
release from damage skeletal muscle tissue, in vivo, has not yet
been quantified and remains a significant priority. Of particular
importance is the acknowledgement that the source of Ang II
could also be a result of a local RAS within the muscle vasculature,
the inflammatory response associated with muscle damage, arrive
through systemic sources [38], or any combination of these
scenarios. Therefore, further investigation into the contribution
and localization of Ang II secretion in response to muscle injury is
necessary.
Chemotaxis can be best viewed as a cyclical process involving
cellular polarization, extension, contraction and detachment
[35,41,42]. Interestingly, Ang II appeared to enhance numerous
aspects of this process. Integral to the initiation of chemotaxis is
the formation of actin-rich lamellipodia that serve to directionally
extend the migrating cell forward [43]. The present results
demonstrate that Ang II treatment induced cytoskeletal reorgani-
zation and increased the number of cells possessing lamellipodia
consistent with other reports demonstrating actin cytoskeletal
rearrangement and lamellipodial formation in Ang II induced
migration [36,37]. MMP2 is a gelatinase that is known to regulate
migration by facilitating detachment from the ECM as well as
increasing the space for cellular expansion as the cell migrates
toward the degraded matrix [41]. We chose to focus our attention
on MMP2 for two reasons. Firstly, this is the primary MMP
expressed in myoblasts [44] and secondly, we demonstrate that
Ang II increased myoblast invasion through gelatin covered
transwells. In agreement with the current study, El Fahime and
colleagues [44] reported that pharmacological inhibition of MMPs
severely inhibited in vivo migration of transplanted C2C12
myoblasts while overexpression of MMP2 significantly increased
their in vivo migratory capacity.
Ang II possesses the capacity to bind to two distinct receptor
subtypes, AT1 and AT2 [45]. We have previously demonstrated
that both C2C12 and primary myoblasts express both of these
receptor subtypes and therefore either could regulate Ang II
mediated migration. Our results highlight the role of AT1a
signaling as AT1a
2/2 primary myoblasts were severely impaired
(62% reduction compared to controls) in their basal migratory
capacity and did not respond to exogenous Ang II treatment.
Interestingly, IHC staining of the AT1 receptor revealed its
localization to lamellipodial projections in myoblasts. The
functional significance of this relationship is currently unknown,
however, the G-coupled chemokine receptors CCR2 and CCR5
redistribute to the leading edge of the cell during chemotaxis in
lymphocytes (Nieto et al. 1997) and natural killer cells [46].
Similarly, the receptor for urokinase-type plasminogen activator
undergoes translocalization to the leading edge of migrating
human monocytes [47]. Therefore, the localization of AT1 at the
leading edge may promote site directed accumulation of pro-
migratory signalling molecules.
Collectively, our findings identify Ang II as a novel regulator of
skeletal muscle growth through modulating muscle satellite cell
activation and migration. Clinically, ACE inhibitors and angio-
tensin receptor blockers are amongst the most commonly
prescribed medications [16] with .65 million individuals in the
United States considered clinically hypertensive with the highest
prevalence in the elderly [48,49]. Unfortunately this population is
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recent observational study by Onder and colleagues [50]
demonstrated that chronic ACE inhibitor treatment slowed the
age-related decline in muscle strength in elderly, hypertensive
women. Although the mechanisms underlying this observation are
not understood, these seemingly conflicting findings punctuate the
importance of understanding the role of Ang II in skeletal muscle
and highlights the need for further investigation into the effects of
Ang II signaling inhibition in elderly individuals undergoing
pharmacological blockade of Ang II signaling.
Supporting Information
Figure S1 Methocellulose culturing synchronizes C2C12
cells in G1. Representative cell cycle profile of flow cytometry
analysis of PI stained C2C12 cells cultured in (A) GM or (B) 1.5%
methocellulose for 72 h (n=5 per group).
(TIF)
Figure S2 Ang II treatment does not induce prolifera-
tion or alter cell cycle kinetics of C2C12 myoblasts.
Representative flow cytometery profiles of BrdU staining of (A)
quiescent control and (B) Ang II treated C2C12 cells (n=6 per
group). Representative cell cycle profiles of 7AAD staining in (C)
control and (D) Ang II treated C2C12 cells (n=6 per group).
(TIF)
Figure S3 Depiction of the under agarose migration
assay.
(TIF)
Figure S4 Ang II treatment increases myoblast chemo-
taxis and invasion. A) Analysis C2C12 myoblasts either directly
treated (Ang II on top) or subjected to a concentration gradient
(Ang II on bottom) of Ang II. B) Analysis of the capacity of control
and Ang II treated C2C12 cells to invade gelatin coated transwells
(n=6 per group). Data are presented as mean 6 s.e.m *indicates a
significant difference (p,0.05) from control.
(TIF)
Figure S5 AT1 colocalizes with lamellipodial projec-
tions. IHC staining of (A) DAPI, (B) AT1, (C) phalloidin and (D)
merge in C2C12 myoblasts (100x magnification). Arrows indicate
colocalization of AT1 to lamellipodial projections of a polarized
cell.
(TIF)
Figure S6 H&E stain of TA sections at 21d of regener-
ation. H&E stains at low magnification (10X) demonstrate that 1)
all fibres contain central nuclei demonstrating homogeneity of
injury, and 2) fibres from captopril treated animals were obviously
smaller.
(TIF)
Figure S7 Comparison of AT1a
2/2 and control unin-
jured CSA. Representative sections of uninjured TA muscles
from control and AT1a
2/2 mice demonstrate no difference in
mean fibre CSA.
(TIF)
Figure S8 BrdU incorporation into freshly isolated
satellite cells treated with Ang II. Additional evidence
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